These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
417 related articles for article (PubMed ID: 33275756)
21. Refractory anemia with ring sideroblasts (RARS) and RARS with thrombocytosis (RARS-T): 2017 update on diagnosis, risk-stratification, and management. Patnaik MM; Tefferi A Am J Hematol; 2017 Mar; 92(3):297-310. PubMed ID: 28188970 [TBL] [Abstract][Full Text] [Related]
22. Chronic neutrophilic leukemia and atypical chronic myeloid leukemia: 2024 update on diagnosis, genetics, risk stratification, and management. Szuber N; Orazi A; Tefferi A Am J Hematol; 2024 Jul; 99(7):1360-1387. PubMed ID: 38644693 [TBL] [Abstract][Full Text] [Related]
23. Myelodysplastic syndrome/myeloproliferative neoplasm with ring sideroblasts and thrombocytosis: Ringing in a new future. Nathan DI; Feld J; El Jamal SM; Mascarenhas J; Tremblay D Leuk Res; 2022 Apr; 115():106820. PubMed ID: 35279478 [TBL] [Abstract][Full Text] [Related]
24. Definitions, Biology, and Current Therapeutic Landscape of Myelodysplastic/Myeloproliferative Neoplasms. Gerke MB; Christodoulou I; Karantanos T Cancers (Basel); 2023 Jul; 15(15):. PubMed ID: 37568631 [TBL] [Abstract][Full Text] [Related]
25. Chronic myeloid neoplasms harboring concomitant mutations in myeloproliferative neoplasm driver genes (JAK2/MPL/CALR) and SF3B1. Ok CY; Trowell KT; Parker KG; Moser K; Weinberg OK; Rogers HJ; Reichard KK; George TI; Hsi ED; Bueso-Ramos CE; Tam W; Orazi A; Bagg A; Arber DA; Hasserjian RP; Wang SA Mod Pathol; 2021 Jan; 34(1):20-31. PubMed ID: 32694616 [TBL] [Abstract][Full Text] [Related]
26. Progression in Myeloid Neoplasms: Beyond the Myeloblast. Faria C; Tzankov A Pathobiology; 2024; 91(1):55-75. PubMed ID: 37232015 [TBL] [Abstract][Full Text] [Related]
28. 3q26/EVI1 rearrangement in myelodysplastic/myeloproliferative neoplasms: An early event associated with a poor prognosis. Hu Z; Hu S; Ji C; Tang Z; Thakral B; Loghavi S; Medeiros LJ; Wang W Leuk Res; 2018 Feb; 65():25-28. PubMed ID: 29288910 [TBL] [Abstract][Full Text] [Related]
29. Clinicopathologic characterisation of myeloid neoplasms with concurrent spliceosome mutations and myeloproliferative-neoplasm-associated mutations. Liu YC; Illar GM; Bailey NG J Clin Pathol; 2020 Nov; 73(11):728-736. PubMed ID: 32217616 [TBL] [Abstract][Full Text] [Related]
30. Co-mutation pattern, clonal hierarchy, and clone size concur to determine disease phenotype of SRSF2 Todisco G; Creignou M; Gallì A; Guglielmelli P; Rumi E; Roncador M; Rizzo E; Nannya Y; Pietra D; Elena C; Bono E; Molteni E; Rosti V; Catricalá S; Sarchi M; Dimitriou M; Ungerstedt J; Vannucchi AM; Hellström-Lindberg E; Ogawa S; Cazzola M; Malcovati L Leukemia; 2021 Aug; 35(8):2371-2381. PubMed ID: 33349666 [TBL] [Abstract][Full Text] [Related]
31. Refractory anemia with ring sideroblasts (RARS) and RARS with thrombocytosis: "2019 Update on Diagnosis, Risk-stratification, and Management". Patnaik MM; Tefferi A Am J Hematol; 2019 Apr; 94(4):475-488. PubMed ID: 30618061 [TBL] [Abstract][Full Text] [Related]
32. Driver somatic mutations identify distinct disease entities within myeloid neoplasms with myelodysplasia. Malcovati L; Papaemmanuil E; Ambaglio I; Elena C; Gallì A; Della Porta MG; Travaglino E; Pietra D; Pascutto C; Ubezio M; Bono E; Da Vià MC; Brisci A; Bruno F; Cremonesi L; Ferrari M; Boveri E; Invernizzi R; Campbell PJ; Cazzola M Blood; 2014 Aug; 124(9):1513-21. PubMed ID: 24970933 [TBL] [Abstract][Full Text] [Related]
33. Diagnosing myelodysplastic/myeloproliferative neoplasms: laboratory testing strategies to exclude other disorders. Hall J; Foucar K Int J Lab Hematol; 2010 Dec; 32(6 Pt 2):559-71. PubMed ID: 20670271 [TBL] [Abstract][Full Text] [Related]
34. Juvenile myelomonocytic leukemia - A bona fide RASopathy syndrome. Lasho T; Patnaik MM Best Pract Res Clin Haematol; 2020 Jun; 33(2):101171. PubMed ID: 32460983 [TBL] [Abstract][Full Text] [Related]
35. Clinical management of myelodysplastic syndrome/myeloproliferative neoplasm overlap syndromes. Clara JA; Sallman DA; Padron E Cancer Biol Med; 2016 Sep; 13(3):360-372. PubMed ID: 27807503 [TBL] [Abstract][Full Text] [Related]
36. Myelodysplastic/myeloproliferative neoplasms with ring sideroblasts and thrombocytosis (MDS/MPN-RS-T): Mayo-Moffitt collaborative study of 158 patients. Mangaonkar AA; Lasho TL; Ketterling RP; Reichard KK; Gangat N; Al-Kali A; Begna KH; Pardanani A; Al Ali NH; Talati C; Sallman D; Padron E; Patnaik MM; Tefferi A; Komrokji R Blood Cancer J; 2022 Feb; 12(2):26. PubMed ID: 35105856 [TBL] [Abstract][Full Text] [Related]
37. [Genomic aberrations in myelodysplastic syndromes and related disorders]. Makishima H Rinsho Ketsueki; 2019; 60(6):600-609. PubMed ID: 31281151 [TBL] [Abstract][Full Text] [Related]
38. Linder K; Iragavarapu C; Liu D Biomark Res; 2017; 5():33. PubMed ID: 29225884 [TBL] [Abstract][Full Text] [Related]
39. I walk the other line: myelodysplastic/myeloproliferative neoplasm overlap syndromes. Gerds AT Curr Hematol Malig Rep; 2014 Dec; 9(4):400-6. PubMed ID: 25195196 [TBL] [Abstract][Full Text] [Related]
40. Myelodysplastic Syndromes/Myeloproliferative Overlap Neoplasms and Differential Diagnosis in the WHO and ICC 2022 Era: A Focused Review. Fontana D; Elli EM; Pagni F; Piazza R Cancers (Basel); 2023 Jun; 15(12):. PubMed ID: 37370785 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]